In a clinical study of the medicinal product, antibodies to the protein eptotermin alfa were detected in 194 out of 207 (94%) patients treated with it and 18 out of 86 (21%) treated with autograft bone (control group).
Ravimi kliinilises uuringus leiti 207st eptotermin alfa ravitud patsiendist 194- l (94%) ning 86st 18- l (21%) luulise autograftiga ravitud (kontrollgrupi) patsiendil proteiini eptotermin alfa antikehad.